HEM Pharma signs 4.6 billion KRW probiotic supply contract with Access Business Group, boosting revenue outlook
HEM Pharma has entered into a supply contract for new probiotic products with Access Business Group.
The contract value is approximately 4.6 billion KRW, representing 35.71% of its 2025 consolidated revenue, a significant order.
The contract period runs from June 23, 2026 to October 9, 2026, with payment due within 60 days of invoice receipt.
The company has performed similar contracts with this counterparty in the last three years, indicating a stable business relationship.
[AI Summary]This contract presents a meaningful revenue opportunity in HEM Pharma's core probiotic business and is expected to positively impact short-term earnings. However, as it is a single order, investors should monitor the sustainability of future orders.